LONDON, March 6,
2023 /PRNewswire/ -- Smith+Nephew (LSE:SN,
NYSE:SNN), the global medical technology company, today announces a
systemic literature review and meta-analysis1 of its
VISIONAIRE Patient-Specific Instrumentation (PSI) showing that its
use leads to improvements in alignment accuracy, efficiency in
surgical procedures, and reduction in length of hospital stay in
comparison with conventional instrumentation.1
The research was published online by the Archives of Orthopaedic
and Trauma Surgery. Twenty-five (25) relevant studies were included
in the meta-analysis, all of which compared VISIONAIRE PSI-enabled
Total Knee Arthroplasty (TKA) with conventional
instrumentation-enabled TKA. Each study reported on one or more of
the following outcome measures: alignment accuracy, intraoperative
outcomes (indicative of efficiency), and postoperative
outcomes.
The studies demonstrate that, compared to TKA carried out with
conventional instrumentation, patients who received VISIONAIRE
PSI-enabled TKA experienced the following statistically significant
results:
- A 40% reduction in the odds of an outlier in the mechanical
axis.
- More efficient operations, with reductions in operating room
time, turnover time, and tourniquet time.
- A 53% reduction in the odds of requiring a blood
transfusion.
- An 11.1% reduction in mean length of hospital stay.
Accurate alignment (+/-3 degrees from neutral) has been shown to
correlate with long term arthroplasty survivorship.2-4
This meta-analysis provides evidence of reduced odds of mechanical
axis outliers versus conventional instrumentation.
"Utilizing Smith+Nephew's VISIONAIRE preoperative planning and
intraoperative cutting guides has allowed me to be more accurate,
less invasive, and more efficient with both inpatient and
outpatient total knee replacements," commented Dr. Ravi Bashyal, Orthopedic Surgeon and Director of
Outpatient Hip and Knee Replacement Surgery at NorthShore
University HealthSystem. "This has resulted in improved outcomes,
streamlined tray utilization, and ultimately a happier, more
satisfied surgeon and patients. It's even been shown in a
retrospective study that total hospital costs were statistically
significantly lower for TKA with VISIONAIRE than TKA without
PSI.5"
Smith+Nephew's VISIONAIRE Patient-Specific Instrumentation
includes customized cutting guides designed to reduce the number of
steps and surgical instruments required for surgery compared to
conventional TKA, creating a simplified surgical
environment,1,6 with virtually no in-hospital
incremental costs for payors, with post-acute cost savings due to a
reduction in the likelihood of readmissions.5 The guides are
designed from surgeon-specific preferences, then developed by a
dedicated engineer, allowing for personalised performance.
To learn more about Smith+Nephew's VISIONAIRE Patient-Specific
Instrumentation, please visit
https://www.smith-nephew.com/en/health-care-professionals/products/orthopaedics/visionaire
References
- Tibesku CO et al. Comparison of clinical outcomes of VISIONAIRE
patient–specific instrumentation with conventional instrumentation
in total knee arthroplasty: a systematic literature review and
meta–analysis. Ach Orthop Trauma Surg. 2022
- Jeffery RS et al. Coronal alignment after total knee
replacement. J Bone Joint Surg Br. 1991;73(5):709–714
- Marimuthu K et al. A multi-planar CT-based comparative analysis
of patient-specific cutting guides with conventional
instrumentation in total knee arthroplasty. J Arthroplasty.
2014;29(6):1138–1142
- Ritter MA et al. Postoperative alignment of total knee
replacement. Its effect on survival. Clin Orthop Relat Res.
1994;299:153–6
- Thomas S et al. Total hospital costs and readmission rate of
Patient-Specific Instrument in total knee arthroplasty patients. J
Knee Surg. 2022;35(02):113-121
- Abane L et al. A comparison of patient-specific and
conventional instrumentation for total knee arthroplasty: A
multicentre randomised controlled trial. Bone and Joint Journal.
2015;97(1):56-63 show less
About Smith+Nephew
Smith+Nephew is a portfolio medical technology company focused
on the repair, regeneration and replacement of soft and hard
tissue. We exist to restore people's bodies and their self-belief
by using technology to take the limits off living. We call this
purpose 'Life Unlimited'. Our 19,000 employees deliver this mission
every day, making a difference to patients' lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
franchises of Orthopaedics, Sports Medicine & ENT and Advanced
Wound Management.
Founded in Hull, UK, in 1856,
we now operate in more than 100 countries, and generated annual
sales of $5.2 billion in 2022.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and follow us
on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may
or may not prove accurate. For example, statements regarding
expected revenue growth and trading margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of COVID-19, such as the depth and longevity
of its impact, government actions and other restrictive measures
taken in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
COVID-19; economic and financial conditions in the markets we
serve, especially those affecting health care providers, payers and
customers (including, without limitation, as a result of COVID-19);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers
(including, without limitation, as a result of COVID-19);
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that
Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
™Trademark of Smith+Nephew. Certain marks
registered US Patent and Trademark Office.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/smithnephews-visionaire-patient-specific-instrumentation-shown-to-improve-outcome-measures-for-total-knee-arthroplasty-compared-with-conventional-instrumentation-301762121.html
SOURCE Smith & Nephew plc